Safety and Efficacy of Faricimab in Patients With NPDR (MAGIC)
Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial
Sponsor: Genentech, Inc.
A PHASE2 clinical study on Non-Proliferative Diabetic Retinopathy, this trial is ongoing. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Greater Houston Retina Research
For direct contact, visit the study record on ClinicalTrials.gov .